• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

贝伐单抗治疗非小细胞肺癌患者高血压的发病率及风险：一项随机对照试验的荟萃分析

Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.

作者信息

Chen Jian, Lu Yingfeng, Zheng Yunliang

机构信息

Intensive Care Unit, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

出版信息

Drug Des Devel Ther. 2015 Aug 18;9:4751-60. doi: 10.2147/DDDT.S87258. eCollection 2015.

DOI:10.2147/DDDT.S87258
PMID:26316712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4547635/
Abstract

AIM

A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in non-small-cell lung cancer (NSCLC) patients.

MATERIALS AND METHODS

Electronic databases such as the Embase, PubMed, and Cochrane Library were searched for related trials. Statistical analyses were conducted to calculate the overall incidence rates, odds ratios (ORs), and 95% confidence intervals (CIs) by using either random-effect or fixed-effect models depending on the heterogeneity.

RESULTS

A total of 3,155 subjects from nine studies were included. The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%-34.3%) and 6.95% (95% CI 5.81%-8.30%). Bevacizumab use was associated with a significantly increased risk in all-grade hypertension (OR 8.07, 95% CI 3.87-16.85; P=0.0002) and high-grade hypertension (OR 5.93, 95% CI 3.41-10.32; P<0.0001). No evidence of publication bias was determined for the ORs of hypertension in our meta-analysis.

CONCLUSION

Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. Early monitoring and effective management of hypertension might be important steps for the safe use of this drug.

摘要

目的

开展一项研究以确定贝伐单抗用于非小细胞肺癌（NSCLC）患者时高血压的总体风险及发生率。

材料与方法

检索Embase、PubMed和Cochrane图书馆等电子数据库以查找相关试验。根据异质性采用随机效应或固定效应模型进行统计分析，以计算总体发生率、比值比（OR）和95%置信区间（CI）。

结果

共纳入来自9项研究的3155名受试者。NSCLC患者中所有级别和高级别高血压的总体发生率分别为19.55%（95%CI 10.17%-34.3%）和6.95%（95%CI 5.81%-8.30%）。使用贝伐单抗与所有级别高血压（OR 8.07，95%CI 3.87-16.85；P=0.0002）和高级别高血压（OR 5.93，95%CI 3.41-10.32；P<0.0001）的风险显著增加相关。在我们的荟萃分析中，未确定高血压OR存在发表偏倚的证据。

结论

贝伐单抗与NSCLC患者发生高血压的风险显著增加相关。早期监测和有效管理高血压可能是安全使用该药物的重要措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/fe756f25aca0/dddt-9-4751Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/d137d967cee8/dddt-9-4751Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/ea7837d0ad7b/dddt-9-4751Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/c08e0e976323/dddt-9-4751Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/85df7c435ade/dddt-9-4751Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/f0c537b30b1e/dddt-9-4751Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/fe756f25aca0/dddt-9-4751Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/d137d967cee8/dddt-9-4751Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/ea7837d0ad7b/dddt-9-4751Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/c08e0e976323/dddt-9-4751Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/85df7c435ade/dddt-9-4751Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/f0c537b30b1e/dddt-9-4751Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f3d/4547635/fe756f25aca0/dddt-9-4751Fig6.jpg

相似文献

1
Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.贝伐单抗治疗非小细胞肺癌患者高血压的发病率及风险：一项随机对照试验的荟萃分析
Drug Des Devel Ther. 2015 Aug 18;9:4751-60. doi: 10.2147/DDDT.S87258. eCollection 2015.
2
Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis.贝伐单抗治疗非小细胞肺癌患者的感染风险与发生率：一项荟萃分析
Oncol Res Treat. 2022;45(5):281-290. doi: 10.1159/000522390. Epub 2022 Feb 3.
3
Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials.贝伐珠单抗治疗非小细胞肺癌患者的风险特征：一项随机对照试验的荟萃分析。
Acta Oncol. 2012 Feb;51(2):151-6. doi: 10.3109/0284186X.2011.631579. Epub 2011 Nov 16.
4
Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.贝伐珠单抗治疗晚期非鳞状非小细胞肺癌：一种循证方法。
Oncology. 2011;80(5-6):350-8. doi: 10.1159/000328781. Epub 2011 Jul 27.
5
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.癌症患者使用帕唑帕尼的高血压发病率和风险：一项荟萃分析。
Cancer Chemother Pharmacol. 2013 Feb;71(2):431-9. doi: 10.1007/s00280-012-2025-5. Epub 2012 Nov 21.
6
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.贝伐珠单抗增加癌症患者发生重度高血压的风险：一项荟萃分析。
Am J Hypertens. 2010 May;23(5):460-8. doi: 10.1038/ajh.2010.25. Epub 2010 Feb 25.
7
Value of bevacizumab in treatment of colorectal cancer: A meta-analysis.贝伐单抗在结直肠癌治疗中的价值：一项荟萃分析。
World J Gastroenterol. 2015 Apr 28;21(16):5072-80. doi: 10.3748/wjg.v21.i16.5072.
8
[Bevacizumab and arterial hypertension or proteinuria: management].[贝伐单抗与动脉高血压或蛋白尿：管理]
Rev Mal Respir. 2008 Jun;25(6):767-72. doi: 10.1016/s0761-8425(08)73804-x.
9
Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.贝伐珠单抗增加癌症患者发生严重出血的风险：一项荟萃分析。
Oncology. 2010;79(1-2):27-38. doi: 10.1159/000314980. Epub 2010 Nov 3.
10
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）联合贝伐单抗用于表皮生长因子受体（EGFR）突变的非小细胞肺癌的再挑战治疗
Cancer Chemother Pharmacol. 2015 Oct;76(4):835-41. doi: 10.1007/s00280-015-2867-8. Epub 2015 Sep 8.

引用本文的文献

1
Respiratory Pathology and Cardiovascular Diseases: A Scoping Review.呼吸病理学与心血管疾病：一项范围综述
Open Respir Arch. 2024 Nov 23;7(1):100392. doi: 10.1016/j.opresp.2024.100392. eCollection 2025 Jan-Mar.
2
Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.贝伐单抗治疗复发性高级别胶质瘤的剂量与疗效：一项回顾性研究
Cancer Manag Res. 2024 Nov 16;16:1617-1626. doi: 10.2147/CMAR.S481289. eCollection 2024.
3
Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta-analysis.

本文引用的文献

1
Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art.非小细胞肺癌的辅助化疗：最新进展。
Transl Lung Cancer Res. 2015 Apr;4(2):191-7. doi: 10.3978/j.issn.2218-6751.2014.06.01.
2
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.晚期非鳞状非小细胞肺癌患者在接受顺铂、吉西他滨和贝伐单抗诱导化疗后，改用口服长春瑞滨和贝伐单抗进行维持治疗：一项II期研究。
Med Oncol. 2015 Apr;32(4):134. doi: 10.1007/s12032-015-0587-x. Epub 2015 Mar 22.
3
接受贝伐珠单抗联合化疗治疗结直肠癌患者的高血压和血栓栓塞风险：系统评价和荟萃分析。
Cancer Med. 2023 Dec;12(24):21579-21591. doi: 10.1002/cam4.6662. Epub 2023 Dec 8.
4
The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers.贝伐单抗治疗肺癌和结肠癌脑转移所致难治性血管源性水肿患者的疗效。
Front Oncol. 2022 Sep 29;12:838670. doi: 10.3389/fonc.2022.838670. eCollection 2022.
5
Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors.澳大利亚接受血管信号通路抑制剂治疗的癌症患者中高血压治疗的发生率及危险因素。
Discov Oncol. 2022 Jan 20;13(1):6. doi: 10.1007/s12672-022-00468-3.
6
Clinical Significance of CYFRA21-1, AFP, CA-153, CEA, and CA-199 in the Diagnosis of Lung Cancer Ocular Metastasis in Hypertension Population.CYFRA21-1、甲胎蛋白、CA-153、癌胚抗原及CA-199在高血压人群肺癌眼转移诊断中的临床意义
Front Cardiovasc Med. 2021 Sep 14;8:670594. doi: 10.3389/fcvm.2021.670594. eCollection 2021.
7
Etiology and management of hypertension in patients with cancer.癌症患者高血压的病因及管理
Cardiooncology. 2021 Apr 6;7(1):14. doi: 10.1186/s40959-021-00101-2.
8
Cardiovascular Screening and Lipid Management in Breast Cancer Survivors.乳腺癌幸存者的心血管筛查和血脂管理。
J Am Board Fam Med. 2020 Nov-Dec;33(6):894-902. doi: 10.3122/jabfm.2020.06.190459.
9
Associations between untraditional risk factors, pneumonia/lung cancer, and hospital fatality among hypertensive men in Guangzhou downtown.广州市中心高血压男性中的非传统危险因素、肺炎/肺癌与医院病死率之间的关系。
Sci Rep. 2020 Jan 29;10(1):1425. doi: 10.1038/s41598-020-58207-z.
10
Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs.螺内酯，一种经典的保钾利尿剂，可降低生存素表达并使癌细胞对非DNA损伤性抗癌药物产生化疗增敏作用。
Cancers (Basel). 2019 Oct 14;11(10):1550. doi: 10.3390/cancers11101550.
Meta-analyses: what is heterogeneity?
荟萃分析：何为异质性？
BMJ. 2015 Mar 16;350:h1435. doi: 10.1136/bmj.h1435.
4
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.卡铂、S-1和吉非替尼作为一线三联化疗方案用于治疗具有表皮生长因子受体激活突变的晚期非小细胞肺癌患者的II期试验。
Med Oncol. 2015 Mar;32(3):40. doi: 10.1007/s12032-014-0474-x. Epub 2015 Jan 25.
5
Anti-VEGF Therapy with Bevacizumab--limited cardiovascular toxicity.使用贝伐单抗的抗血管内皮生长因子治疗——心血管毒性有限。
Asian Pac J Cancer Prev. 2014;15(24):10769-72. doi: 10.7314/apjcp.2014.15.24.10769.
6
Bevacizumab for metastatic colon cancer: does patient BMI influence survival?贝伐单抗治疗转移性结肠癌：患者体重指数会影响生存率吗？
Anticancer Drugs. 2015 Mar;26(3):363-6. doi: 10.1097/CAD.0000000000000201.
7
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.一项关于端粒酶抑制剂艾美拉唑作为晚期非小细胞肺癌维持治疗的随机II期研究。 （注：原文中“imetelstat”翻译为“艾美拉唑”可能有误，正确的应该是“艾美司他” ，但按照要求不添加解释，故按原文翻译呈现。）
Ann Oncol. 2015 Feb;26(2):354-62. doi: 10.1093/annonc/mdu550. Epub 2014 Dec 2.
8
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.血管生成抑制剂在晚期非小细胞肺癌中的疗效与安全性：一项系统评价与荟萃分析
J Cancer Res Clin Oncol. 2015 May;141(5):909-21. doi: 10.1007/s00432-014-1862-5. Epub 2014 Nov 6.
9
Predicting adult weight change in the real world: a systematic review and meta-analysis accounting for compensatory changes in energy intake or expenditure.预测现实世界中的成人体重变化：一项考虑能量摄入或消耗代偿性变化的系统评价和荟萃分析
Int J Obes (Lond). 2015 Aug;39(8):1181-7. doi: 10.1038/ijo.2014.184. Epub 2014 Oct 17.
10
Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.人类结肠癌中TIA-1的可变剪接调控血管内皮生长因子（VEGF）异构体表达、血管生成、肿瘤生长及贝伐单抗耐药性。
Mol Oncol. 2015 Jan;9(1):167-78. doi: 10.1016/j.molonc.2014.07.017. Epub 2014 Aug 20.